ReCode Therapeutics
MENLO PARK, California · Biotechnology, Healthcare, Health Care
ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.
Key facts
- Headquarters
- MENLO PARK, California
- Employees
- Unknown
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Private
- Website
- http://recodetx.com/
- Company page
Recent activity at ReCode Therapeutics
- : ReCode Therapeutics secures investment from Cystic Fibrosis Foundation to enhance research collaboration for a gene editing therapy targeting cystic fibrosis.
- : ReCode Therapeutics has raised over $29 million in additional financing to advance its genetic medicines pipeline, supported by $3 million from the Cystic Fibrosis Foundation.
- : ReCode Therapeutics secured up to $15 million in a corporate round led by the Cystic Fibrosis Foundation to develop a gene editing therapy for cystic fibrosis.
- : RECODE THERAPEUTICS
- : Recode Therapeutics Announces Closing Of Extension To Series B Financing
- : ReCode Therapeutics Appoints Erica Jefferson as Senior Vice President of Corporate Affairs
- : RECODE THERAPEUTICS
- : Recode Therapeutics Announces Strategic Investment From The Cystic Fibrosis Foundation To Accelerate Development Of Novel Mrna Therapy
- : RECODE THERAPEUTICS, INC.
- : Recode Therapeutics To Expand Next-Generation Delivery Platform And Diversify Genetic Medicines Pipeline With Oversubscribed Series B Financing Totaling $200M
ReCode Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2025 | Funding Round | $29.0M |
| Nov 2024 | Corporate Round | $15.0M |
| Sep 2023 | Venture | $259.8M |
| Sep 2023 | Series B | Undisclosed |
| Jan 2023 | Venture | $210.0M |
Leadership
- Trisha, Member Board of Directors
- David Lockhart, Executive Officer, Director
- Peter Thompson, Director
- Helen Kim, Director
- Edward Hurwitz, Director
- RA II, Director
- Oleg Nodelman, Director
- Rana Al-Hallaq, Director
- David Lockhart, Executive Officer, Director
- Michael Torres, Director
- RA II, Director
- Edward Hurwitz, Director
Verified email and direct lines for ReCode Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
ReCode Therapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
ReCode Therapeutics in the news
Companies similar to ReCode Therapeutics
- Olema Pharmaceuticals, Inc. · Biotechnology, Healthcare, Health Care
- Oruka Therapeutics · Biotechnology, Healthcare, Health Care
- iSpecimen · Biotechnology, Healthcare, Health Care
- Avalon Globocare Corp. · Biotechnology, Healthcare, Health Care
- Beam Therapeutics Inc. · Biotechnology, Healthcare, Health Care
About ReCode Therapeutics: questions and answers
What does ReCode Therapeutics do?
ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.
Where is ReCode Therapeutics headquartered?
ReCode Therapeutics is headquartered in MENLO PARK, California.
Has ReCode Therapeutics raised funding?
Yes. Fundz has recorded 5 funding events for ReCode Therapeutics. The most recent, Funding Round of $29.0M, was in Sep 2025.
What is the latest news on ReCode Therapeutics?
On Aug 07, 2026, ReCode Therapeutics secures investment from Cystic Fibrosis Foundation to enhance research collaboration for a gene editing therapy targeting cystic fibrosis.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy